NasdaqGS:AXGT

Stock Analysis Report

Executive Summary

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases.

Snowflake

Fundamentals

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has Axovant Gene Therapies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.4%

AXGT

0.8%

US Biotechs

1.0%

US Market


1 Year Return

-69.8%

AXGT

-8.3%

US Biotechs

6.7%

US Market

Return vs Industry: AXGT underperformed the US Biotechs industry which returned -8.3% over the past year.

Return vs Market: AXGT underperformed the US Market which returned 6.7% over the past year.


Share holder returns

AXGTIndustryMarket
7 Day-2.4%0.8%1.0%
30 Day-25.6%-3.9%-1.8%
90 Day-24.7%-3.5%-1.8%
1 Year-69.8%-69.8%-7.5%-8.3%9.1%6.7%
3 Year-94.5%-94.5%13.6%9.6%46.1%36.6%
5 Yearn/a3.3%-1.7%66.9%48.6%

Price Volatility Vs. Market

How volatile is Axovant Gene Therapies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Axovant Gene Therapies undervalued based on future cash flows and its price relative to the stock market?

4.44x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: Insufficient data to calculate AXGT's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate AXGT's fair value to establish if it is undervalued.


Price Based on Earnings

PE vs Industry: AXGT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: AXGT is unprofitable, so we can't compare its PE Ratio to the US market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate AXGT's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: AXGT is overvalued based on its PB Ratio (4.4x) compared to the US Biotechs industry average (2.5x).


Next Steps

Future Growth

How is Axovant Gene Therapies expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

56.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: AXGT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AXGT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AXGT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if AXGT's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if AXGT's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: Insufficient data to determine if AXGT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Axovant Gene Therapies performed over the past 5 years?

-6.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: AXGT is unprofitable, and losses have increased over the past 5 years at a rate of -6.8% per year.

Accelerating Growth: Unable to compare AXGT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AXGT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: AXGT has a negative Return on Equity (-358.52%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: AXGT is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: AXGT is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Axovant Gene Therapies's financial position?


Financial Position Analysis

Short Term Liabilities: AXGT's short term assets ($91.7M) exceeds its short term liabilities ($54.0M)

Long Term Liabilities: AXGT's short term assets (91.7M) exceeds its long term liabilities (18.1M)


Debt to Equity History and Analysis

Debt Level: AXGT's debt to equity ratio (134.2%) is considered high

Reducing Debt: Insufficient data to determine if AXGT's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: AXGT has a low level of unsold assets or inventory.

Debt Coverage by Assets: AXGT's debt is covered by short term assets (assets are 2.329360x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AXGT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: AXGT has sufficient cash runway for 1.434069 years if free cash flow continues to reduce at historical rates of -14.1% each year.


Next Steps

Dividend

What is Axovant Gene Therapies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate AXGT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AXGT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if AXGT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AXGT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AXGT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Axovant Gene Therapies's salary, the management and board of directors tenure and is there insider trading?

1.7yrs

Average management tenure


CEO

Pavan Cheruvu (37yo)

1.7yrs

Tenure

US$1,028,744

Compensation

Dr. Pavan Cheruvu, M.D., has been Chief Executive Officer of Axovant Sciences Ltd. since February 12, 2018 and as its Director since September 26, 2018. Dr. Cheruvu provides medical oversight for Hale’s wo ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Pavan's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Pavan's compensation has been consistent with company performance over the past year.


Management Age and Tenure

1.7yrs

Average Tenure

53.5yo

Average Age

Experienced Management: AXGT's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Age and Tenure

1.1yrs

Average Tenure

60yo

Average Age

Experienced Board: AXGT's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$39,07517 Jun 19
Pavan Cheruvu
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares7,500
Max PriceUS$5.21
BuyUS$17,59517 Jun 19
Atul Pande
EntityIndividual
Role
Lead Director
Lead Independent Director
Shares3,370
Max PriceUS$5.22
BuyUS$10,000,00119 Mar 19
Roivant Sciences Ltd.
EntityCompany
Shares833,333.38
Max PriceUS$12.00
BuyUS$10,000,00020 Dec 18
Roivant Sciences Ltd.
EntityCompany
Shares1,250,000
Max PriceUS$8.00

Ownership Breakdown


Management Team

  • David Nassif (65yo)

    CFO, Principal Accounting Officer & General Counsel

    • Tenure: 0.3yrs
  • Gavin Corcoran (56yo)

    Chief R&D Officer of Axovant Sciences

    • Tenure: 1.3yrs
    • Compensation: US$1.37m
  • Greg MacMichael

    Senior VP of Technical Operations

    • Tenure: 0.9yrs
  • Ilise Lombardo

    Chief Medical Officer

    • Tenure: 4.5yrs
  • Marianne Dinsmore (51yo)

    Head of Global Transactions & Risk Management

    • Tenure: 4.6yrs
    • Compensation: US$1.07m
  • Pavan Cheruvu (37yo)

    CEO & Director

    • Tenure: 1.7yrs
    • Compensation: US$1.03m
  • Shankar Ramaswamy

    Chief Business Officer

    • Tenure: 1.7yrs
  • Fraser Wright

    Chief Technology Officer

    • Tenure: 1.8yrs
  • Tricia Truehart

    Head of Investor Relations

    • Tenure: 0yrs
  • Parag Meswani

    Senior VP of Commercial Strategy & Operations

    • Tenure: 0.9yrs

Board Members

  • Myrtle Potter (61yo)

    Director

    • Tenure: 1.1yrs
    • Compensation: US$274.08k
  • Michael Hayden (68yo)

    Senior Scientific Advisor & Chairman of the Scientific Advisory Board

    • Tenure: 1.4yrs
  • George Bickerstaff (63yo)

    Independent Director

    • Tenure: 1.7yrs
    • Compensation: US$57.75k
  • Berndt A. Modig (60yo)

    Independent Director

    • Tenure: 4.6yrs
    • Compensation: US$63.25k
  • Atul Pande (64yo)

    Lead Independent Director

    • Tenure: 1.1yrs
    • Compensation: US$71.50k
  • Frank Torti (40yo)

    Chairperson

    • Tenure: 1.1yrs
    • Compensation: US$282.00k
  • Ilan Oren (35yo)

    Director

    • Tenure: 1.3yrs
  • Pavan Cheruvu (37yo)

    CEO & Director

    • Tenure: 1.7yrs
    • Compensation: US$1.03m
  • Senthil Sundaram (41yo)

    Director

    • Tenure: 0.3yrs

Company Information

Axovant Gene Therapies Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Axovant Gene Therapies Ltd.
  • Ticker: AXGT
  • Exchange: NasdaqGS
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$130.305m
  • Shares outstanding: 22.78m
  • Website: https://www.axovant.com

Number of Employees


Location

  • Axovant Gene Therapies Ltd.
  • 11-12 St. James's Square
  • 3rd Floor
  • London
  • Greater London
  • SW1Y 4LB
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AXGTNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDJun 2015
3ASAMUN (Boerse Muenchen)YesCommon SharesDEEURJun 2015
3ASADB (Deutsche Boerse AG)YesCommon SharesDEEURJun 2015

Biography

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company’s current pi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 03:01
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)